Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine

Leukemia and Lymphoma

Volumn 58, Issue 8, 2017, Pages 2011-2013

  Saini, Lalit ^a   Chua, Neil ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZACITIDINE; BILIRUBIN; BLEOMYCIN; C REACTIVE PROTEIN; CARMUSTINE; CD11B ANTIGEN; CD33 ANTIGEN; CD38 ANTIGEN; CD7 ANTIGEN; CHLORAMBUCIL; CISPLATIN; CREATINE KINASE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; HLA DR ANTIGEN; NIVOLUMAB; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; PROCARBAZINE; STEM CELL FACTOR RECEPTOR; TOBRAMYCIN; VANCOMYCIN; VINBLASTINE; VINCRISTINE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE MYELOID LEUKEMIA; ADULT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG MEGADOSE; ECHOGRAPHY; EDITORIAL; ERYTHROCYTE SEDIMENTATION RATE; FASCIA; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; HYPEREMIA; HYPERPLASIA; HYPOALBUMINEMIA; IMMUNOPHENOTYPING; KARYOTYPE; LOWER LIMB; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL EDEMA; POSITRON EMISSION TOMOGRAPHY; TISSUE NECROSIS; COMPLICATION; SECOND CANCER; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; HODGKIN DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MAGNETIC RESONANCE IMAGING; MALE; MYOSITIS; NEOPLASMS, SECOND PRIMARY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 85003881390     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428194.2016.1265115     Document Type: Editorial

References (10)

1. Sehgal A, Whiteside TL, Boyiadzis M., Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opin Biol Ther. 2015;15:1191–1203.
2. Orskov AD, Treppendahl MB, Skovbo A, et al. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients:a rationale for combined targeting of PD-1 and DNA methylation. Oncotarget. 2015;6:9612–9626.
3. Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280–1288.
4. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France:International Agency for Research on Cancer; 2008.
5. Bristol-Myers Squibb Canada. Nivolumab product monograph; 2015.
6. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330.
7. Yoshioka M, Kambe N, Yamamoto Y, et al. Case of respiratory discomfort due to myositis after administration of nivolumab. J Dermatol. 2015;42:1008–1009.
8. Bohan A, Peter JB, Bowman RL, et al. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977;56:255–286.
9. Malik A, Hayat G, Kalia JS, et al. Idiopathic inflammatory myopathies:clinical approach and management. Front Neurol. 2016;7:64. doi:10.3389/fneur.2016.00064.
10. Van De Vlekkert J, Maas M, Hoogendijk JE, et al. Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy. Muscle Nerve. 2015;51:253–258.